Baldwin Wealth Partners LLC MA Sells 1,205 Shares of Stryker Co. (NYSE:SYK)

Baldwin Wealth Partners LLC MA trimmed its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 12.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,140 shares of the medical technology company's stock after selling 1,205 shares during the quarter. Baldwin Wealth Partners LLC MA's holdings in Stryker were worth $3,030,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Stryker by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after purchasing an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Stryker by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock worth $4,000,056,000 after acquiring an additional 54,693 shares during the period. FMR LLC boosted its holdings in shares of Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after acquiring an additional 168,436 shares during the period. Finally, Norges Bank bought a new position in shares of Stryker in the fourth quarter worth $1,710,744,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 0.2%

Shares of SYK traded down $0.65 during trading hours on Thursday, hitting $380.43. The company had a trading volume of 877,833 shares, compared to its average volume of 1,328,826. The firm has a market cap of $145.21 billion, a P/E ratio of 49.02, a P/E/G ratio of 2.93 and a beta of 0.91. The stock's 50 day moving average price is $371.23 and its 200 day moving average price is $375.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.50 earnings per share. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's dividend payout ratio is presently 45.41%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Citigroup reaffirmed a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Truist Financial raised their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Finally, The Goldman Sachs Group set a $422.00 price objective on Stryker in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.